What is LabGenius?
Headquartered in London, LabGenius operates at the intersection of computer science and molecular biology. Its core discovery engine, EVA, utilizes a sophisticated feedback loop that combines synthetic biology with high-throughput robotic experimentation. This unique approach allows the company to navigate complex protein landscapes with unprecedented speed and precision. By digitizing the discovery process, LabGenius effectively reduces the time and cost associated with developing novel therapeutic proteins, providing a scalable solution for the pharmaceutical industry's most pressing challenges in drug design and optimization.
How much funding has LabGenius raised?
LabGenius has raised a total of $73.2M across 3 funding rounds:
Angel/Seed
$3.7M
Series A
$25M
Series B
$44.5M
Angel/Seed (2017): $3.7M with participation from Acequia Capital, Berggruen Holdings, System.One., Beast Ventures, and Kindred Capital
Series A (2020): $25M led by Felicis Ventures, Atomico, Chris Gibson, Inovia Capital, Lux Capital, Patrick Pichette, The Obvious, and Air Street Capital
Series B (2024): $44.5M supported by LG, Octopus Ventures, and M/ventures
Key Investors in LabGenius
Atomico
A prominent European venture capital firm founded by Skype co-founder Niklas Zennström, focusing on scaling technology companies across the continent.
Lux Capital
A New York-based venture capital firm specializing in early-stage and growth-stage investments at the intersection of frontier science, AI, and biotechnology.
Felicis Ventures
A Menlo Park-based venture capital firm that supports founders through multistage funds, with a strong track record in AI, SaaS, and high-growth technology sectors.
What's next for LabGenius?
With the recent influx of capital, LabGenius is well-positioned to scale its operational capacity and expand its internal pipeline of therapeutic candidates. The company's strategic roadmap focuses on deepening its machine learning capabilities to further refine the predictive accuracy of the EVA platform. As the firm transitions into a more mature enterprise phase, the focus will likely shift toward establishing high-value partnerships with global pharmaceutical entities and accelerating the transition of its lead programs into clinical development. This growth trajectory reflects a broader industry trend where data-driven, automated platforms are becoming the standard for high-stakes biological research.
See full LabGenius company page
